Copyright
©The Author(s) 2024.
World J Virol. Dec 25, 2024; 13(4): 96573
Published online Dec 25, 2024. doi: 10.5501/wjv.v13.i4.96573
Published online Dec 25, 2024. doi: 10.5501/wjv.v13.i4.96573
Table 1 Patient characteristics (n = 60)
| Demographics | |
| Age median (IQR) | 30 (24-35) |
| Gestational week median (IQR) | 36 (30-38) |
| Comorbidities (%) | |
| Hypertension | 1 (1.66) |
| Diabetes | 3 (5) |
| Hypothyroidism | 5 (8.5) |
| BMI > 30 | 3 (5) |
| Hematologic condition | 4 (6.8) |
| Former OB/GYN pathology | 3 (5) |
| Symptomatology | |
| Days from onset median (IQR) | 3 (2-7) |
| Asymptomatic (%) | 27 (45) |
| Fever (%/symptomatic) | 18 (54.5) |
| Dyspnea (%/symptomatic) | 11 (33.3) |
| Cough (%/symptomatic) | 19 (57.6) |
| Contractions (%/symptomatic) | 11 (33.3) |
| Pregnancy outcomes (%) | |
| Preterm delivery | 18 (30) |
| Fetal clinical abnormalities | 4 (6.6) |
| Neonatal ICU admission | 6 (10) |
| Miscarriage | 1 (1.66) |
| Still birth | 2 (3.33) |
| SGA | 3 (5) |
| CS due to ARDS | 2 (3.33) |
| Maternal outcomes (%) | |
| Hospitalization | 15 (25) |
| Survival | 60 (100) |
| IMV | 4 (6.6) |
| Pharmacologic management (%) | |
| Corticosteroids | 25 (41.6) |
| Remdesivir | 13 (21.6) |
Table 2 Hospitalized vs non-hospitalized pregnant women, n (%)
| Hospitalized (n = 15) | Not hospitalized (n = 45) | P value | |
| Demographics | |||
| Age median (IQR) | 34 (23-40) | 29.67 (26-34) | 0.36 |
| Former smokers | 2 (13.3) | 6 (13.3) | 0.584 |
| BMI > 30 | 3 (20) | 0 (0) | 0.013 |
| At least one co-morbidity | 4 (26.6) | 6 (13.3) | 0.25 |
| Gestational week median (IQR) | 30 (26-36) | 36 (34-38) | 0.031 |
| Clinical manifestations | |||
| Asymptomatic | 0 (0) | 27 (37.7) | < 0.001 |
| Days from onset median (IQR) | 7 (2-9) | 2 (2-3) | 0.006 |
| Fever (symptomatic) | 10 (66.6) | 8 (17.7) | 0.2 |
| Dyspnoea (symptomatic) | 11 (73.3) | 0 (0) | < 0.001 |
| Cough (symptomatic) | 11 (73.3) | 8 (17.7) | 0.09 |
| Contractions (symptomatic) | 2 (13.3) | 16 (35.5) | 0.026 |
| Disease severity | |||
| WHO CPS median (IQR) | 5 (5-6) | 2 (1-4) | < 0.001 |
| P/F < 400 | 10 (66.6) | 3 (20) | < 0.001 |
| Need for NIV | 6 (13.3) | 0 (0) | < 0.001 |
| Need for IMV | 4 (8.8) | 0 (0) | < 0.001 |
| Pharmacological management | |||
| Corticosteroids | 13 (86.6) | 12 (26.6) | < 0.001 |
| Remdesivir | 8 (53.3) | 5 (11.1) | 0.02 |
| Pregnancy outcomes | |||
| Preterm delivery | 5 (33.3) | 13 (28.8) | 0.745 |
| Composite adverse perinatal | 5 (33.3) | 6 (13.3) | 0.09 |
| Laboratory values median (IQR) | |||
| WBC (Κ/μL) | 6980 (5580-8320) | 9110 (7380-11150) | 0.01 |
| LYMPH (Κ/μL) | 1.142 (0.785-1.570) | 1.300 (1.020-1.880) | 0.102 |
| CPK (ng/mL) | 69 (20-94) | 65.5 (35-164) | 0.179 |
| LDH (IU/L) | 318 (258-376) | 210 (178-283) | 0.001 |
| CRP (mg/dL) | 5.94 (2.09-9.81) | 2.34 (1.02-4.47) | 0.028 |
| Ferritin (ng/mL) | 149 (101-140) | 74 (34.5-95.5) | 0.001 |
| D-Dimers (μg/mL) | 1.470 (0.670-2.180) | 1.492 (1.045-2.215) | 0.303 |
- Citation: Akinosoglou K, Schinas G, Papageorgiou E, Karampitsakos T, Dimakopoulou V, Polyzou E, Tzouvelekis A, Marangos M, Papageorgiou D, Spernovasilis N, Adonakis G. COVID-19 in pregnancy: Perinatal outcomes and complications. World J Virol 2024; 13(4): 96573
- URL: https://www.wjgnet.com/2220-3249/full/v13/i4/96573.htm
- DOI: https://dx.doi.org/10.5501/wjv.v13.i4.96573
